Fenebrutinib Shows Noninferiority to Ocrelizumab in Primary Progressive MS In patients with primary progressive MS, fenebrutinib appeared to reduce progression risk by 12% compared with ocrelizumab.

#Fenebrutinib met its primary endpoint in the phase 3 #FENtrepid trial evaluating the therapy for primary progressive multiple sclerosis (#MS), according to data Genentech presented at the 2026 ACTRIMS Forum in San Diego.

Read here: https://bit.ly/3Zsio93

#RareDisease #MultipleSclerosis